Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence - Center for Biosimilars
  Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone - OncLive
  Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product - Pharmacy Times
  Sandoz, on a $1.1B investment spree in Slovenia, breaks ground at new $440M biosimilar plant - Fierce Pharma
  Sandoz breaks ground on new European biosimilar plant - European Pharmaceutical Review
  Amgen asserts swathes of patents against Biocon, Henlius and Hikma in latest biosimilar spats - IAM Patent
  Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach - Sandoz
  The FDA’s Biosimilar Burden—and How Congress Can Lift It - Cato Institute